EP0644765A4 - METAL POWDER COMPOSITIONS CONTAINING BINDERS FOR HIGH TEMPERATURE COMPRESSION. - Google Patents

METAL POWDER COMPOSITIONS CONTAINING BINDERS FOR HIGH TEMPERATURE COMPRESSION.

Info

Publication number
EP0644765A4
EP0644765A4 EP93914110A EP93914110A EP0644765A4 EP 0644765 A4 EP0644765 A4 EP 0644765A4 EP 93914110 A EP93914110 A EP 93914110A EP 93914110 A EP93914110 A EP 93914110A EP 0644765 A4 EP0644765 A4 EP 0644765A4
Authority
EP
European Patent Office
Prior art keywords
interleukin
inhibition
treatment
cellular hyperproliferation
hyperproliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93914110A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0644765A1 (en
Inventor
Kevin D Cooper
Craig Hammerberg
Kameron W Maxwell
Ben Y Tseng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
University of Michigan
Original Assignee
Genta Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc, University of Michigan filed Critical Genta Inc
Publication of EP0644765A1 publication Critical patent/EP0644765A1/en
Publication of EP0644765A4 publication Critical patent/EP0644765A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
EP93914110A 1992-05-22 1993-05-21 METAL POWDER COMPOSITIONS CONTAINING BINDERS FOR HIGH TEMPERATURE COMPRESSION. Withdrawn EP0644765A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88773492A 1992-05-22 1992-05-22
US887734 1992-05-22
PCT/US1993/004917 WO1993024134A1 (en) 1992-05-22 1993-05-21 Treatment of cellular hyperproliferation by inhibition of interleukin-1

Publications (2)

Publication Number Publication Date
EP0644765A1 EP0644765A1 (en) 1995-03-29
EP0644765A4 true EP0644765A4 (en) 1997-02-26

Family

ID=25391751

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93914110A Withdrawn EP0644765A4 (en) 1992-05-22 1993-05-21 METAL POWDER COMPOSITIONS CONTAINING BINDERS FOR HIGH TEMPERATURE COMPRESSION.

Country Status (9)

Country Link
EP (1) EP0644765A4 (es)
JP (1) JPH07508977A (es)
KR (1) KR950701528A (es)
AU (1) AU4388993A (es)
CA (1) CA2136349A1 (es)
IL (1) IL105741A0 (es)
MX (1) MX9302951A (es)
NZ (1) NZ253509A (es)
WO (1) WO1993024134A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
ATE428785T1 (de) 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL133913A0 (en) * 1997-07-10 2001-04-30 Therakos Inc Treatment of inflammatory disorders of the bowel and urinary bladder
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
GB0607189D0 (en) * 2006-04-10 2006-05-17 Polybiomed Ltd interleukin IL 1ra composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006702A1 (en) * 1988-01-21 1989-07-27 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
WO1991015226A1 (en) * 1990-04-09 1991-10-17 The American National Red Cross Rejuvenation compositions and methods for their use
WO1992021353A1 (en) * 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
WO1993005071A1 (en) * 1991-08-30 1993-03-18 Sterling Winthrop Inc. INTERLEUKIN 1β PROTEASE AND INTERLEUKIN 1β PROTEASE INHIBITORS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006702A1 (en) * 1988-01-21 1989-07-27 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
WO1991015226A1 (en) * 1990-04-09 1991-10-17 The American National Red Cross Rejuvenation compositions and methods for their use
WO1992021353A1 (en) * 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
WO1993005071A1 (en) * 1991-08-30 1993-03-18 Sterling Winthrop Inc. INTERLEUKIN 1β PROTEASE AND INTERLEUKIN 1β PROTEASE INHIBITORS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AAPS (AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS) EIGHTH ANNUAL MEETING AND EXPOSITION, ORLANDO, FLORIDA, USA, NOVEMBER 14-18, 1993. *
HAMMERBERG, C. ET AL.: "Interleukin - 1 receptor antagonist in normal and psoriatic epidermis.", JOURNAL OF CLINICAL INVESTIGATION, (1992 AUG) 90 (2) 571-83., XP000615300 *
MANSON, J. ET AL.: "Modulation of interleukin 1beta gene expression using antisense phosphorothioate oligonucleotides", LYMPHOKINE RES. 9 (1990);35-42, XP002021245 *
MILLER, K. ET AL.: "In vitro transdermal flux and tissue distribution of interleukin 1-beta antisense methyl phosphonate oligonucleotide from topical formulations.", PHARMACEUTICAL RESEARCH (NEW YORK) 10 (10 SUPPL.). S252. ABSTRACT PDD7310, October 1993 (1993-10-01), XP002021246 *
See also references of WO9324134A1 *

Also Published As

Publication number Publication date
AU4388993A (en) 1993-12-30
MX9302951A (es) 1994-07-29
KR950701528A (ko) 1995-04-28
EP0644765A1 (en) 1995-03-29
WO1993024134A1 (en) 1993-12-09
NZ253509A (en) 1999-09-29
JPH07508977A (ja) 1995-10-05
IL105741A0 (en) 1993-09-22
CA2136349A1 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
ZA933519B (en) Treatment of wastewater
GB9226860D0 (en) Novel treatment
AP9200459A0 (en) Treatment of wastewater
EP0644765A4 (en) METAL POWDER COMPOSITIONS CONTAINING BINDERS FOR HIGH TEMPERATURE COMPRESSION.
GB2270909B (en) Sewage treatment
EP0630383A4 (en) METHODS OF TREATING DIABETES.
GB9203039D0 (en) Treatment
GB9211148D0 (en) Novel treatment
GB9225860D0 (en) Novel treatment
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
GB9201920D0 (en) Novel treatment i
ZA931063B (en) Treatment of glaucoma.
GB9203535D0 (en) Novel treatment iii
GB9206442D0 (en) Treatment chamber
ITRM920305A1 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
FI945200A0 (fi) Jäteveden puhdistus
EP0609335A4 (en) Methods for the treatment of hyperlipidemia using azaspiranes.
ZA93348B (en) Treatment of liquids.
GB9203637D0 (en) Novel treatment
GB2260131B (en) Sewage treatment
GB9108786D0 (en) Effluent treatment
ZA929644B (en) Treatment of wastewater.
GB9110733D0 (en) Sewage treatment
GB9206523D0 (en) Sewage treatment
GB9201973D0 (en) Effluent treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970110

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990830

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991202